Neuroprotective actions of sex steroids in Parkinson’s disease
Introduction
Sex steroids are involved in functions that extend beyond reproduction. Estrogen actions are implicated in cognition, synaptic plasticity, memory, neurogenesis and neuroprotection [22]. Hormone therapy is commonly used to compensate for ovarian hormone deficits at menopause and has been associated with a lower risk of Parkinson’s disease (PD) [34] and Alzheimer’s disease [80]. Several variables can influence the beneficial effects of hormone therapy [105], [162]. Here, we review the effect of estrogen, progesterone and androgens in the brain with an emphasis on animal models of PD as well as the molecular mechanisms implicated in estrogen neuroprotection.
Section snippets
Parkinson’s disease, estrogens and sex differences
PD is the second most common neurodegenerative disorder mainly characterized by a progressive and selective depletion of dopamine (DA) neurons in the substantia nigra [83]. Typically, a greater incidence and prevalence of PD is described in men [5], [20], [99], [103], [112], [114], [129], [177], (meta-analysis: [184] reviews: [35], [162]) whereas no sex difference was also reported [43]. This sex difference suggests a beneficial influence of estrogens against the development and progression of
Models of Parkinson’s disease
The sex differences and effects of estrogens in PD reviewed in the previous section have fueled research in animal models to decipher which steroid is active and under what conditions. Moreover, hormonal modulation and protection of brain neurotransmission has received much attention in the last two decades [45], [48], [105], [126], [127]. The neuroprotective effects of estrogen have been studied in various in vitro and in vivo experimental models. Beneficial effects of estradiol are observed
Estrogens and neuroprotection
Estrogens are steroidal compounds; the main physiological molecules are estradiol, estrone and estriol. Estrone and estriol as well as the stereoisomer 17α-estradiol have less affinity on estrogen receptors (ERs) than 17β-estradiol [95]. The protective properties of these estrogens have been investigated in various experimental models of brain injury. Studies report that estrone has beneficial effects against kainate, FeCl2, NMDA, serum deprivation, glutamate, β-amyloid peptide, glucose
Mechanisms of steroid hormone actions
The mechanisms of steroid hormone actions are complex and multifaceted. These mechanisms can vary with dose, site of action and sex. Since much of the work on mechanisms has been conducted with estradiol and estradiol plays a key role in neuroprotection of the dopaminergic system as described in this review, we will concentrate on this gonadal steroid.
Akt signaling in human diseases
Akt is a major regulator of metabolism, cell growth, cell proliferation, transcription and cell survival [111], [152] and was shown to be modulated by estrogens (previous section). Dysfunction of this protein kinase is associated with various diseases in human including cancer [10], diabetes [3] and schizophrenia [90]. A positive association of the Akt1 haplotype to methamphetamine-use disorder has been reported in Japanese [84]. Akt1 variants were associated with risk of schizophrenia [170]
Conclusion
Significant sex differences exist in nigro-striatal DA neurodegeneration as observed in animal models as well as clinical and epidemiological reports on PD. Since sex steroid hormones represent the most salient factor related to sex differences, the influences of estrogens, androgens and progesterone were assessed in regards to their contributions to these sex differences in nigro-striatal DA neurodegeneration. The female sex steroids 17β-estradiol and progesterone but not the male steroids
Acknowledgments
This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) to T.D.P. and by a studentship from the Fonds d’Enseignement et de Recherche (FER) of the Faculté de Pharmacie de l’Université Laval to M.B. The Research Incentive Program of NEOUCOM provided support to D.E.D.
References (199)
- et al.
Major sex differences in non-genomic estrogen actions on intracellular signaling in mouse brain in vivo
Neuroscience
(2005) - et al.
Effects of neonatal and prepubertal hormonal manipulations upon estrogen neuroprotection of the nigrostriatal dopaminergic system within female and male mice
Neuroscience
(2005) - et al.
The Akt-GSK-3 signaling cascade in the actions of dopamine
Trends Pharmacol Sci
(2007) - et al.
Oestrogens and extrapyramidal system
Lancet
(1977) - et al.
Activation of AKT kinases in cancer: implications for therapeutic targeting
Adv Cancer Res
(2005) - et al.
Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter
Exp Neurol
(1999) - et al.
Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice
Prog Neuropsychopharmacol Biol Psychiatry
(2008) - et al.
Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity
Biochem Pharmacol
(2007) - et al.
Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications
Steroids
(2007) - et al.
Progesterone receptors: form and function in brain
Front Neuroendocrinol
(2008)
Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway
Curr Opin Neurobiol
17-Beta estradiol rapidly enhances extracellular signal-regulated kinase 2 phosphorylation in the rat brain
Neuroscience
Dendrite loss is a characteristic early indicator of toxin-induced neurodegeneration in rat midbrain slices
Exp Neurol
Synergistic interaction of estradiol and insulin-like growth factor-I in the activation of PI3K/Akt signaling in the adult rat hypothalamus
Brain Res Mol Brain Res
Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist
Neuropharmacology
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Cell
Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice
Brain Res
Methamphetamine–gonadal steroid hormonal interactions: effects upon acute toxicity and striatal dopamine concentrations
Neurotoxicol Teratol
Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice
Neurotoxicol Teratol
CREB is a regulatory target for the protein kinase Akt/PKB
J Biol Chem
CREB: a major mediator of neuronal neurotrophin responses
Neuron
Oxygen radicals diminish dopamine transporter function in rat striatum
Eur J Pharmacol
G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane
Biochem Biophys Res Commun
The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system
Brain Res
Tamoxifen abolishes estrogen’s neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system
Neuroscience
Glycogen synthase kinase 3beta links neuroprotection by 17beta-estradiol to key Alzheimer processes
Neuroscience
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling
Prog Neurobiol
ERK1/2 antagonizes glycogen synthase kinase-3beta-induced apoptosis in cortical neurons
J Biol Chem
The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis
Neuroscience
Ageing and neurotoxins as causative factors in idiopathic Parkinson’s disease – a critical analysis of the neurochemical evidence
Prog Neuropsychopharmacol Biol Psychiatry
The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia
Pharmacol Ther
Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains
Eur J Pharmacol
Estradiol prevents the injury-induced decrease of 90 ribosomal S6 kinase (p90RSK) and Bad phosphorylation
Neurosci Lett
Expression of estrogen receptor-alpha and beta mRNA in the developing and adult mouse striatum
Neurosci Lett
Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions
Biol Pharm Bull
Anti-oxidative neuroprotection by estrogens in mouse cortical cultures
J Korean Med Sci
Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging
Neurology
Oestrogen as a neuroprotective hormone
Nat Rev Neurosci
Neuroprotection against oxidative stress by estrogens: structure–activity relationship
Mol Pharmacol
Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case-control study
Mov Disord
Modification of dopamine transporter function: effect of reactive oxygen species and dopamine
J Neurochem
Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes
Mol Endocrinol
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study
Neurology
Neuroprotection by rasagiline: a new therapeutic approach to Parkinson’s disease?
CNS Drug Rev
Virtual and biomolecular screening converge on a selective agonist for GPR30
Nat Chem Biol
Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990
Neurology
Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system
J Endocrinol
Multiple pathways transmit neuroprotective effects of gonadal steroids
Endocrine
Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (Mpp+) towards dopaminergic mesencephalic neurones in primary culture
J Neurochem
Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice
Synapse
Cited by (199)
Sex differences in neuroimmunoendocrine communication. Involvement on longevity
2023, Mechanisms of Ageing and DevelopmentDoes dopamine deficiency affect sex-dependent prognosis in Parkinson's disease?
2022, Parkinsonism and Related DisordersRepositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
2022, European Journal of PharmacologyCitation Excerpt :Several studies have associated estrogen levels with a positive effect on PD risk, which could explain the decreased risk of PD in women (Bourque et al., 2019; Villa et al., 2016). These results are supported by preclinical studies showing that estrogen treatment exerts beneficial effects on dopamine and its metabolite levels and protects the integrity of dopaminergic neurons, preventing neuronal loss in PD models (Bourque et al., 2009; Morale et al., 2006; Tripanichkul et al., 2006). Furthermore, glial cells seem to be involved in the estrogen neuroprotection, since estrogens receptors are expressed by these cells in the striatum (Almey et al., 2012).